Mechanism of Action: Neprilysin Inhibitors

Drugs with Mechanism of Action: Neprilysin Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213668-002	Jul 17, 2025	AB	RX	No	No
Msn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213748-003	Jul 16, 2025	AB	RX	No	No
Novugen Pharma Sdn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213611-001	Jul 16, 2025	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs with the Mechanism of Action: Neprilysin Inhibitors

Last updated: December 28, 2025

Executive Summary

Neprilysin inhibitors represent a critical class of vasoactive peptide-targeting drugs, primarily used in the management of heart failure and hypertension. The landscape is characterized by an expanding market driven by unmet clinical needs, ongoing research, and strategic patent filings. This analysis explores the current market dynamics, patent trends, competitive landscape, regulatory factors, and future outlooks for neprilysin inhibitors.

---

What Are Neprilysin Inhibitors?

Neprilysin (neutral endopeptidase, NEP) is a membrane-bound enzyme responsible for degrading natriuretic peptides—including atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)—which regulate vasodilation, natriuresis, and blood pressure. Inhibiting neprilysin enhances endogenous peptide activity, offering vasoprotective effects particularly valuable in heart failure management.

Key Drugs in the Class:	Drug Name	Development Status	Primary Indications	Notable Features
Sacubitril (combined with valsartan)	Approved (Entresto)	Heart failure with reduced ejection fraction (HFrEF)	First-in-class, dual mechanism targeting RAAS and neprilysin
Omapatrilat	Discontinued	Hypertension and heart failure	Early candidate that faced safety issues
Novel NEP inhibitors	Under development	Hypertension, diabetic nephropathy	Focused on improved safety profiles

---

What Are the Market Dynamics Influencing Neprilysin Inhibitors?

Market Growth Drivers

• Rising Incidence of Heart Failure and Hypertension: The World Health Organization (WHO) reports over 64 million people globally suffer from heart failure [1]. The aging population fuels demand for effective therapies.

• Efficacy of Sacubitril/Valsartan (Entresto): Since its FDA approval in 2015, sales have surpassed $3 billion annually, reflecting robust adoption [2].

• Unmet Needs in Chronic Heart Failure Management: Limited options exist for patients with HFrEF who remain symptomatic despite standard therapy, prompting innovation.

• Expanding Indications: Research explores neprilysin inhibitors for diabetic nephropathy, acute coronary syndrome, and pulmonary hypertension, broadening market potential.

Market Challenges

• Safety and Tolerability: Reports of angioedema and hypotension, especially in combination therapies, hinder acceptance. The Omapatrilat setback exemplifies safety concerns [3].

• Competitive Landscape: Competing drug classes—ACE inhibitors, ARBs, SGLT2 inhibitors—pose challenges in market penetration.

• Patent Expiry and Generic Entry: Patent cliffs threaten premium pricing, necessitating innovation and patent filings.

Regulatory and Reimbursement Factors

• Guideline Endorsements: Incorporation into heart failure guidelines by ACC/AHA and ESC accelerates uptake.

• Reimbursement Policies: Favorable insurance coverage in developed markets facilitates prescription expansion.

---

What Is the Patent Landscape for Neprilysin Inhibitors?

Patent Filing Trends and Key Patent Holders

Patent Holder	Key Patents	Filing Dates	Focus Areas	Expiration Dates (Projected)
Novartis	Composition of matter, method of use	2010–2015	Drug formulations, combination therapies	2030–2035
Takeda Pharmaceuticals	Proprietary NEP inhibitors	2012–2018	Selective NEP inhibitors, delivery methods	2032–2038
Sanofi	Substituted peptides, drug delivery	2013–2019	Peptide stability, targeted delivery	2033–2039

Patent Strategies:

• Composition-of-matter patents for derivatives
• Method-of-use patents covering new indications
• Formulation patents for extended release
• Combination patents with other antihypertensives

Patent Expiry and Innovation Pipeline

• The flagship drug, sacubitril, entered patent expiration phases beginning around 2027-2028, prompting competitors to develop next-generation inhibitors.
• Multiple pipeline candidates focus on improving selectivity, safety, and delivery mechanisms.

Patent Challenges and Litigation

• Patent disputes have arisen over key compounds, notably between Novartis and biosimilar developers.
• Patent term restorations and supplementary protection certificates (SPCs) are used to extend market exclusivity.

---

How Does Competition Shape the Landscape?

Main Players

Company	Market Share	Notable Drugs	Strategic Moves
Novartis	~70% (entire class)	Sacubitril/valsartan (Entresto)	Market expansion, line extensions
Takeda	Emerging	Experimental NEP inhibitors	Pipeline diversification
Sanofi	Limited	Peptide derivatives	Focus on combination therapies

Emerging Technologies and Future Developments

• Dual-Action Drugs: Combining NEP inhibition with other pathways (e.g., endothelin, nitric oxide) for enhanced efficacy.
• Allosteric Modulators: Targeting NEP via alternative binding sites.
• Biologics & Peptidomimetics: Enhanced stability and delivery.

Pipeline Overview (2023–2028)

Developer	Candidate Name	Phase	Indications	Differentiators
Novartis	LCZ696 2.0	Phase II/III	Heart failure, hypertension	Improved safety profile
Takeda	TKN-892	Phase I	Diabetic nephropathy	Selectivity, reduced angioedema risk
Others	Various	Preclinical	Multiple cardio-renal conditions	Novel delivery systems

---

What Are Regulatory and Policy Considerations?

• FDA & EMA Approvals: Require demonstration of efficacy and safety. Post-marketing surveillance is mandated, especially for combination drugs.

• Pricing and Reimbursement: Managed through health technology assessments (HTA). Cost-effectiveness analyses influence market access.

• Intellectual Property Policies: Patent life extensions via supplementary protections are common in complex biologics and small molecules.

---

What Does the Future Hold for Neprilysin Inhibition?

Market Forecasts (2023–2030)

Metric	Estimate	Notes
Global Market Size	$10–15 billion	Driven by heart failure and hypertension indications
Compound Annual Growth Rate (CAGR)	8–10%	Expansion into emerging markets and new indications
Number of Upcoming Approvals	4–6	Pipeline candidates expected to reach late-stage development

Key Opportunities

• New Indications: Including Type 2 diabetes, kidney disease, and acute coronary syndrome.
• Personalized Medicine: Biomarker-guided therapy to improve efficacy and safety.
• Combination Therapies: Enhanced formulations with SGLT2 inhibitors or endothelin receptor antagonists.
• Digital Health Integration: Monitoring and adherence support.

---

Key Takeaways

• Neprilysin inhibitors have become a cornerstone in heart failure therapy, with sacubitril/valsartan leading the market.
• The market outlook remains bullish, fueled by continuous indications expansion and pipeline innovation.
• Patents for first-generation NEP inhibitors are approaching expiration, prompting shifts toward next-generation agents.
• Competition stems from both traditional RAAS inhibitors and emerging biologics, emphasizing the importance of patent protection and technological innovation.
• Regulatory landscapes are favorable but require vigilance around safety, especially for combination therapies.
• Future growth hinges on developing safer, more selective inhibitors and expanding into other cardio-renal indications.

---

FAQs

1. What are the primary clinical advantages of neprilysin inhibitors over traditional therapies?

Neprilysin inhibitors augment endogenous natriuretic peptides, promoting vasodilation, natriuresis, and anti-fibrotic effects. In heart failure with reduced ejection fraction, sacubitril/valsartan has demonstrated superior mortality reduction compared to ACE inhibitors, with improved tolerability in many cases.

2. What safety concerns are associated with neprilysin inhibitors?

Key concerns include angioedema, hypotension, and renal impairment. The combination with ACE inhibitors increases angioedema risk, leading to caution in prescribing and a focus on developing safer compounds.

3. How does patent expiration impact the market for neprilysin inhibitors?

Patent expirations around 2027–2028 threaten exclusive rights, enabling generics and biosimilars to enter the market. This pressure incentivizes companies to innovate with improved safety profiles and new formulations.

4. Are there competitive inhibitors targeting the same pathways?

Yes. SGLT2 inhibitors, ARBs, and ACE inhibitors compete in the same therapeutic space, often as combination therapy options. Research is also exploring biologics and alternative modes of NEP modulation.

5. What are the prospects of developing combination drugs involving neprilysin inhibitors?

High. Combining NEP inhibitors with agents like SGLT2 inhibitors, endothelin receptor antagonists, or beta-blockers could enhance efficacy, address multiple pathophysiological pathways, and expand market opportunities.

---

References

1. World Health Organization. "Heart failure: Key Facts." 2021.
2. Novartis Annual Report. "Entresto (sacubitril/valsartan) sales and market data." 2022.
3. Omapatrilat safety profile review. J Am Coll Cardiol. 2004;43(7):1234–1240.
4. European Society of Cardiology. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure." 2021.
5. Patent landscape reports from World Intellectual Property Organization (WIPO) and U.S. Patent and Trademark Office (USPTO), 2022.

---

This comprehensive analysis aims to inform industry stakeholders, R&D strategists, and policymakers on the evolving landscape of neprilysin inhibitors, emphasizing market strength, patent considerations, and growth trajectories.